Muscle-Building Pills Could Transform Aging and Fitness

Several experimental drugs targeting the protein myostatin are in clinical trials, aiming to prevent age-related muscle loss and enhance growth. Research tracing back to the 1990s showed that blocking myostatin in mice produced muscles two to three times normal size, and similar mutations occur naturally in some cattle and dogs. If successful, these treatments could help older adults maintain mobility and independence.

The myostatin discovery emerged from 1990s research into growth-factor proteins, where gene mutations produced mice with dramatically enlarged musculature. This mechanism appears naturally in Belgian Blue cattle and bully whippet dogs, and a 2004 case documented a young boy with unusually large muscles carrying myostatin mutations. However, early myostatin blockers that worked spectacularly in mice proved disappointing in human trials.

A key complication is activin A, a second muscle-shrinking factor binding to the same receptors, requiring dual blockade. Even then, human muscle gains cap around 10 percent versus 50 percent in mice. Additionally, because myostatin belongs to a larger growth-factor superfamily, drugs may inadvertently bind related proteins, raising side-effect concerns.